

## HOTLINE: Effective November 18, 2019

New Test 3001992 Leucine-Rich, Glioma-Inactivated Protein 1 Antibody, IgG with LGI1IGGCSF Reflex to Titer, CSF

Additional Technical Information

Methodology: Semi-Quantitative Indirect Fluorescent Antibody

**Performed:** Wed **Reported:** 1-8 days

Specimen Required: Collect: CSF

Specimen Preparation: Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.15 mL)

Storage/Transport Temperature: Refrigerated.

<u>Unacceptable Conditions:</u> Contaminated, hemolyzed, or severely lipemic specimens.

Stability (collection to initiation of testing): Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

Reference Interval: Less than 1:1

Interpretive Data: Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia, and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes leucine-rich, glioma-inactivated 1 protein (LGI1) transfected cell lines for the detection and semi-quantification of the LGI1 IgG antibody.

See Compliance Statement D: www.aruplab.com/CS

Note: If LGI1 antibody IgG is positive, then LGI1 antibody IgG titer will be added. Additional charges apply.

**CPT Code(s):** 86255; if reflexed, add 86256

New York DOH approval pending. Call for status update.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.